Trials and Tribulations of Non-Inferiority: The Ximelagatran Experience
- 6 December 2005
- journal article
- review article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 46 (11) , 1986-1995
- https://doi.org/10.1016/j.jacc.2005.07.062
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial FibrillationJAMA, 2005
- Ximelagatran: Oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillationJournal of the American College of Cardiology, 2005
- Antithrombotic Therapy in Atrial FibrillationChest, 2004
- National Trends in Antiarrhythmic and Antithrombotic Medication Use in Atrial FibrillationArchives of internal medicine (1960), 2004
- Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trialThe Lancet, 2003
- Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 2: Practical Issues and Specific CasesAnnals of Internal Medicine, 2000
- Equivalence and noninferiority trialsAmerican Heart Journal, 2000
- Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial FibrillationArchives of internal medicine (1960), 1994
- Another view of active-controlled trialsControlled Clinical Trials, 1991
- “Proving the null hypothesis” in clinical trialsControlled Clinical Trials, 1982